395 results on '"Hofmeyr, G. Justus"'
Search Results
2. Factors influencing postpartum haemorrhage detection and management and the implementation of a new postpartum haemorrhage care bundle (E-MOTIVE) in Kenya, Nigeria, and South Africa
- Author
-
Forbes, Gillian, Akter, Shahinoor, Miller, Suellen, Galadanci, Hadiza, Qureshi, Zahida, Fawcus, Sue, Hofmeyr, G Justus, Moran, Neil, Singata-Madliki, Mandisa, Dankishiya, Faisal, Gwako, George, Osoti, Alfred, Thomas, Eleanor, Gallos, Ioannis, Mammoliti, Kristie-Marie, Devall, Adam, Coomarasamy, Arri, Althabe, Fernando, Atkins, Lou, Bohren, Meghan A, and Lorencatto, Fabiana
- Subjects
Biomedical and Clinical Sciences ,Psychology ,Clinical Research ,Behavioral and Social Science ,Health Services ,Health and social care services research ,8.1 Organisation and delivery of services ,Good Health and Well Being ,Humans ,Female ,Postpartum Hemorrhage ,Patient Care Bundles ,Maternal Death ,Kenya ,Nigeria ,South Africa ,Postpartum haemorrhage ,Maternal health ,Low- and middle-income countries ,Clinical care bundle ,Formative research ,Qualitative interviews ,Behaviour Change Wheel ,Implementation interventions ,Information and Computing Sciences ,Medical and Health Sciences ,Health Policy & Services ,Biomedical and clinical sciences - Abstract
BackgroundPostpartum haemorrhage (PPH) is the leading cause of global maternal deaths, accounting for 30-50% of maternal deaths in sub-Saharan Africa. Most PPH-related deaths are preventable with timely detection and initiation of care, which may be facilitated by using a clinical care bundle. We explore influences on current PPH detection and management and on the future implementation of a new PPH bundle (E-MOTIVE) in low-resource, high-burden settings.MethodsSemi-structured qualitative interviews based on the Theoretical Domains Framework were conducted with 45 healthcare providers across nine hospitals in Nigeria, Kenya and South Africa, to identify barriers and enablers to current PPH detection and management and future implementation of a new PPH care bundle. Data were analysed using thematic and framework analysis. The Behaviour Change Wheel was used to identify potential interventions to address identified barriers and enablers.ResultsInfluences on current PPH detection and management fell under 12 domains: Environmental Context and Resources (drug and staff shortages), Skills (limited in-service training), Knowledge (variable understanding of the recommended practice), Behaviour Regulation (limited quality improvement culture), Beliefs about Consequences (drawbacks from inaccurate detection), Emotion (stress from the unpredictability of PPH), Social Influence (teamwork), Memory, Attention and Decision-making (limited guideline use), Social/Professional Role and Identity (role clarity), Beliefs about Capabilities (confidence in managing PPH), Reinforcement (disciplinary procedures) and Goals (PPH as a priority). Influences on bundle uptake included: Beliefs about Consequences (perceived benefits of new blood loss measurement tool), Environmental Context and Resources (high cost of drugs and new tools), Memory, Attention and Decision-making (concerns about whether bundle fits current practice), Knowledge (not understanding 'bundled' approach), Social Influence (acceptance by women and staff) and Intention (limited acceptance of 'bundled' approach over existing practice). These influences were consistent across countries. Proposed interventions included: Education, Training, Modelling (core and new skills), Enablement (monitoring uptake), Persuasion (leadership role) and Environmental Restructuring (PPH emergency trolley/kit).ConclusionsA wide range of individual, socio-cultural and environmental barriers and enablers to improving PPH detection and management exist in these settings. We identified a range of interventions that could improve PPH care and the implementation of new care bundles in this context.Trial registrationClinicalTrials.gov : NCT04341662.
- Published
- 2023
3. High Levels of Pretreatment HIV-1 Drug Resistance Mutations Among South African Women Who Acquired HIV During a Prospective Study
- Author
-
Beesham, Ivana, Parikh, Urvi M, Mellors, John W, Davey, Dvora L Joseph, Heffron, Renee, Palanee-Phillips, Thesla, Bosman, Shannon L, Beksinska, Mags, Smit, Jennifer, Ahmed, Khatija, Makkan, Heeran, Selepe, Pearl, Louw, Cheryl, Kotze, Philip, Hofmeyr, G Justus, Singata‐Madliki, Mandisa, Rees, Helen, Baeten, Jared M, and Wallis, Carole
- Subjects
Medical Microbiology ,Biomedical and Clinical Sciences ,Clinical Sciences ,Antimicrobial Resistance ,Clinical Research ,HIV/AIDS ,Infectious Diseases ,Clinical Trials and Supportive Activities ,Genetics ,Development of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,5.1 Pharmaceuticals ,Evaluation of treatments and therapeutic interventions ,Infection ,Good Health and Well Being ,Adult ,Anti-HIV Agents ,Drug Resistance ,Viral ,Female ,Genotype ,HIV Infections ,HIV Seropositivity ,HIV-1 ,Humans ,Mutation ,Prospective Studies ,Reverse Transcriptase Inhibitors ,South Africa ,Young Adult ,antiretroviral resistance ,women ,pretreatment resistance ,Public Health and Health Services ,Virology ,Clinical sciences ,Epidemiology ,Public health - Abstract
BackgroundPretreatment HIV drug resistance (PDR) undermines individual treatment success and threatens the achievement of UNAIDS 95-95-95 targets. In many African countries, limited data are available on PDR as detection of recent HIV infection is uncommon and access to resistance testing is limited. We describe the prevalence of PDR among South African women with recent HIV infection from the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial.MethodsHIV-uninfected, sexually active women, aged 18-35 years, and seeking contraception were enrolled in the ECHO Trial at sites in South Africa, from 2015 to 2018. HIV testing was done at trial entry and repeated quarterly. We tested stored plasma samples collected at HIV diagnosis from women who seroconverted during follow-up and had a viral load >1000 copies/mL for antiretroviral resistant mutations using a validated laboratory-developed population genotyping assay, which sequences the full protease and reverse transcriptase regions. Mutation profiles were determined using the Stanford Drug Resistance Database.ResultsWe sequenced 275 samples. The median age was 23 years, and majority (98.9%, n = 272) were infected with HIV-1 subtype C. The prevalence of surveillance drug resistance mutations (SDRMs) was 13.5% (n = 37). Nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations were found in 12.4% of women (n = 34). Few women had NRTI (1.8%, n = 5) and protease inhibitor (1.1%, n = 3) mutations. Five women had multiple NRTI and NNRTI SDRMs.ConclusionsThe high levels of PDR, particularly to NNRTIs, strongly support the recent change to the South African national HIV treatment guidelines to transition to a first-line drug regimen that excludes NNRTIs.
- Published
- 2022
4. Improving management of first and second stages of labour in low- and middle-income countries
- Author
-
Hofmeyr, G Justus, Moreri-Ntshabele, Badani, Qureshi, Zahida, Memo, Ndiwo, Hanson, Sarah, Muller, Elani, and Singata-Madliki, Mandisa
- Published
- 2024
- Full Text
- View/download PDF
5. Detection and management of postpartum haemorrhage: Qualitative evidence on healthcare providers' knowledge and practices in Kenya, Nigeria, and South Africa
- Author
-
Akter, Shahinoor, Forbes, Gillian, Miller, Suellen, Galadanci, Hadiza, Qureshi, Zahida, Fawcus, Sue, Hofmeyr, G Justus, Moran, Neil, Singata-Madliki, Mandisa, Amole, Taiwo Gboluwaga, Gwako, George, Osoti, Alfred, Thomas, Eleanor, Gallos, Ioannis, Mammoliti, Kristie-Marie, Coomarasamy, Arri, Althabe, Fernando, Lorencatto, Fabiana, and Bohren, Meghan A
- Subjects
Biomedical and Clinical Sciences ,Midwifery ,Public Health ,Health Sciences ,Reproductive Medicine ,Prevention ,Clinical Research ,Health Services ,8.1 Organisation and delivery of services ,Health and social care services research ,Good Health and Well Being ,maternal health ,postpartum haemorrhage ,maternal mortality ,qualitative research ,formative research ,clinical care bundles ,Biomedical and clinical sciences ,Health sciences ,Psychology - Abstract
BackgroundPostpartum haemorrhage (PPH) is the leading cause of maternal death globally. Most PPH deaths can be avoided with timely detection and management; however, critical challenges persist. A multi-country cluster-randomised trial (E-MOTIVE) will introduce a clinical care bundle for early detection and first-response PPH management in hospital settings. This formative qualitative study aimed to explore healthcare providers' knowledge and practices of PPH detection and management after vaginal birth, to inform design and implementation of E-MOTIVE.MethodsBetween July 2020-June 2021, semi-structured qualitative interviews were conducted with 45 maternity healthcare providers (midwives, nurses, doctors, managers) of nine hospitals in Kenya, Nigeria, and South Africa. A thematic analysis approach was used.ResultsFour key themes were identified, which varied across contexts: in-service training on emergency obstetric care; limited knowledge about PPH; current approaches to PPH detection; and current PPH management and associated challenges. PPH was recognised as an emergency but understanding of PPH varied. Early PPH detection was limited by the subjective nature of visual estimation of blood loss. Lack of expertise on PPH detection and using visual estimation can result in delays in initiation of PPH management. Shortages of trained staff and essential resources, and late inter-hospital referrals were common barriers to PPH management.ConclusionThere are critical needs to address context-specific barriers to early and timely detection and management of PPH in hospital settings. These findings will be used to develop evidence-informed implementation strategies, such as improved in-service training, and objective measurement of blood loss, which are key components of the E-MOTIVE trial (Trial registration: ClinicalTrials.gov: NCT04341662).
- Published
- 2022
6. Formative research to design an implementation strategy for a postpartum hemorrhage initial response treatment bundle (E-MOTIVE): study protocol
- Author
-
Bohren, Meghan A, Lorencatto, Fabiana, Coomarasamy, Arri, Althabe, Fernando, Devall, Adam J, Evans, Cherrie, Oladapo, Olufemi T, Lissauer, David, Akter, Shahinoor, Forbes, Gillian, Thomas, Eleanor, Galadanci, Hadiza, Qureshi, Zahida, Fawcus, Sue, Hofmeyr, G Justus, Al-beity, Fadhlun Alwy, Kasturiratne, Anuradhani, Kumarendran, Balachandran, Mammoliti, Kristie-Marie, Vogel, Joshua P, Gallos, Ioannis, and Miller, Suellen
- Subjects
Reproductive Medicine ,Biomedical and Clinical Sciences ,Public Health ,Health Sciences ,Clinical Research ,Prevention ,Behavioral and Social Science ,Good Health and Well Being ,Female ,Humans ,Kenya ,Motivation ,Nigeria ,Postpartum Hemorrhage ,Pregnancy ,South Africa ,Sri Lanka ,Tanzania ,Maternal health ,Postpartum hemorrhage ,Obstetric hemorrhage ,Care bundle ,Formative research ,Maternal mortality ,Behavior change ,Implementation ,Intervention development ,Paediatrics and Reproductive Medicine ,Obstetrics & Reproductive Medicine ,Reproductive medicine ,Public health - Abstract
BackgroundPostpartum hemorrhage (PPH) is the leading cause of maternal death worldwide. When PPH occurs, early identification of bleeding and prompt management using evidence-based guidelines, can avert most PPH-related severe morbidities and deaths. However, adherence to the World Health Organization recommended practices remains a critical challenge. A potential solution to inefficient and inconsistent implementation of evidence-based practices is the application of a 'clinical care bundle' for PPH management. A clinical care bundle is a set of discrete, evidence-based interventions, administered concurrently, or in rapid succession, to every eligible person, along with teamwork, communication, and cooperation. Once triggered, all bundle components must be delivered. The E-MOTIVE project aims to improve the detection and first response management of PPH through the implementation of the "E-MOTIVE" bundle, which consists of (1) Early PPH detection using a calibrated drape, (2) uterine Massage, (3) Oxytocic drugs, (4) Tranexamic acid, (5) Intra Venous fluids, and (6) genital tract Examination and escalation when necessary. The objective of this paper is to describe the protocol for the formative phase of the E-MOTIVE project, which aims to design an implementation strategy to support the uptake of this bundle into practice.MethodsWe will use behavior change and implementation science frameworks [e.g. capability, opportunity, motivation and behavior (COM-B) and theoretical domains framework (TDF)] to guide data collection and analysis, in Kenya, Nigeria, South Africa, Sri Lanka, and Tanzania. There are four methodological components: qualitative interviews; surveys; systematic reviews; and design workshops. We will triangulate findings across data sources, participant groups, and countries to explore factors influencing current PPH detection and management, and potentially influencing E-MOTIVE bundle implementation. We will use these findings to develop potential strategies to improve implementation, which will be discussed and agreed with key stakeholders from each country in intervention design workshops.DiscussionThis formative protocol outlines our strategy for the systematic development of the E-MOTIVE implementation strategy. This focus on implementation considers what it would take to support roll-out and implementation of the E-MOTIVE bundle. Our approach therefore aims to maximize internal validity in the trial alongside future scalability, and implementation of the E-MOTIVE bundle in routine practice, if proven to be effective.Trial registrationClinicalTrials.gov: NCT04341662.
- Published
- 2021
7. Neglected medium-term and long-term consequences of labour and childbirth: a systematic analysis of the burden, recommended practices, and a way forward
- Author
-
Vogel, Joshua P, Jung, Jenny, Lavin, Tina, Simpson, Grace, Kluwgant, Dvora, Abalos, Edgardo, Diaz, Virginia, Downe, Soo, Filippi, Veronique, Gallos, Ioannis, Galadanci, Hadiza, Katageri, Geetanjali, Homer, Caroline S E, Hofmeyr, G Justus, Liabsuetrakul, Tippawan, Morhason-Bello, Imran O, Osoti, Alfred, Souza, João Paulo, Thakar, Ranee, Thangaratinam, Shakila, and Oladapo, Olufemi T
- Published
- 2024
- Full Text
- View/download PDF
8. Vulnerabilities and reparative strategies during pregnancy, childbirth, and the postpartum period: moving from rhetoric to action
- Author
-
Sheikh, Jameela, Allotey, John, Kew, Tania, Khalil, Halimah, Galadanci, Hadiza, Hofmeyr, G Justus, Abalos, Edgardo, Vogel, Joshua P., Lavin, Tina, Souza, João Paulo, Kaur, Inderjeet, Ram, Uma, Betran, Ana Pilar, Bohren, Meghan A., Oladapo, Olufemi T., and Thangaratinam, Shakila
- Published
- 2024
- Full Text
- View/download PDF
9. Extended balloon labour induction: A single arm proof of concept trial
- Author
-
Matshitsa, Lorato, Mercy-Nkuba, Nassali, and Hofmeyr, G. Justus
- Published
- 2023
- Full Text
- View/download PDF
10. What more can be done? Prioritizing the most promising antenatal interventions to improve birth weight
- Author
-
Awoyemi, Toluwalase, Ayede, Adejumoke I., Bastola, Kalpana, Bhutta, Zulfiqar A., Blencowe, Hannah, Christian, Parul, David, Anna, Hunter, Patricia, Isojärvi, Jaana, Katz, Joanne, De Costa, Ayesha, Erchick, Daniel J., Gibson, Sarah, Goncalves, Bronner P., Gravett, Michael G., Hadji, Maryam, Hazel, Elizabeth, Hofmeyr, G Justus, Kozuki, Naoko, Lee, Anne CC., Magge, Hema, Manasyan, Albert, Mohiddin, Abdulrahman, Morrison, Melissa, Muthiani, Yvonne, Nabwera, Helen, Nakimuli, Annettee, Okong, Pius, Prendergast, Andrew J., Simon, Jonathon, Temmerman, Marleen, Yan, Jian, Koivu, Annariina M., Haapaniemi, Tiia, Askari, Sufia, Bhandari, Nita, Black, Robert E., Chico, R. Matthew, Dewey, Kathryn G., Duggan, Christopher P., Klein, Nigel, Kumar, Somesh, Lawn, Joy E., Manji, Karim, Näsänen-Gilmore, Pieta K., Salasibew, Mihretab, Semrau, Katherine E.A., Ashorn, Ulla, and Ashorn, Per
- Published
- 2023
- Full Text
- View/download PDF
11. Small babies, big risks: global estimates of prevalence and mortality for vulnerable newborns to accelerate change and improve counting
- Author
-
Ashorn, Per, Black, Robert E, Lawn, Joy E, Ashorn, Ulla, Klein, Nigel, Hofmeyr, G Justus, Temmerman, Marleen, Askari, Sufia, Ohuma, Eric O, Moller, Ann-Beth, Bradley, Ellen, Chakwera, Samuel, Hussain-Alkhateeb, Laith, Lewin, Alexandra, Okwaraji, Yemisrach B, Retno Mahanani, Wahyu, White Johansson, Emily, Lavin, Tina, Estevez Fernandez, Diana, Gatica Domínguez, Giovanna, de Costa, Ayesha, Cresswell, Jenny A, Krasevec, Julia, Blencowe, Hannah, Requejo, Jennifer, Moran, Allisyn C, Pingray, Veronica, Cormick, Gabriela, Gibbons, Luz, Belizan, José, Guevel, Carlos, Warrilow, Kara, Gordon, Adrienne, Flenady, Vicki, Sexton, Jessica, Lawford, Harriet, Paixao, Enny S., Rocha Falcão, Ila, Lima Barreto, Mauricio, Lisonkova, Sarka, Wen, Qi, Mardones, Francisco, Caulier-Cisterna, Raúl, Acuña, José, Velebil, Petr, Jirova, Jitka, Horváth-Puhó, Erzsébet, Sørensen, Henrik Toft, Sakkeus, Luule, Abuladze, Liili, Gissler, Mika, Moradi-Lakeh, Maziar, Heidarzadeh, Mohammad, Khalili, Narjes, A. Yunis, Khalid, Al Bizri, Ayah, Nakad, Pascale, Devi Karalasingam, Shamala, R Jeganathan, J Ravichandran, binti Baharum, Nurakman, Suárez-Idueta, Lorena, Barranco Flores, Arturo, Gonzalez Roldan, Jesus F, Lopez Alvarez, Sonia, van Dijk, Aimée E., Broeders, Lisa, Huicho, Luis, Quezada Pinedo, Hugo G, Cajachagua-Torres, Kim N, Carrillo-Larco, Rodrigo M, Tarazona Meza, Carla Estefania, Guzman-Vilca, Wilmer Cristobal, Olukade, Tawa O., Ali, Hamdy A., Alyafei, Fawziya, AlQubaisi, Mai, Alturk, Mohamad R, Kim, Ho Yeon, Cho, Geum Joon, Razaz, Neda, Söderling, Jonas, Smith, Lucy K, Kurinczuk, Jennifer J, Matthews, Ruth J, Manktelow, Bradley N, Draper, Elizabeth S, Fenton, Alan C, Lowry, Estelle, Rowland, Neil, Wood, Rachael, Monteath, Kirsten, Pereyra, Isabel, Pravia, Gabriella, Davis, Celina, Clarke, Samantha, Wu, Lee S.F., Yoshida, Sachiyo, Bahl, Rajiv, Grandi, Carlos, Labrique, Alain B, Rashid, Mabhubur, Ahmed, Salahuddin, Roy, Arunangshu D., Haque, Rezwanul, Shaikh, Saijuddin, Baqui, Abdullah H., Saha, Samir K., Khanam, Rasheda, Rahman, Sayedur, Shapiro, Roger, Zash, Rebecca, Silveira, Mariângela F., Buffarini, Romina, Kolsteren, Patrick, Lachat, Carl, Huybregts, Lieven, Roberfroid, Dominique, Zeng, Lingxia, Zhu, Zhonghai, He, Jianrong, Qui, Xiu, Gebreyesus, Seifu H., Tesfamariam, Kokeb, Bekele, Delayehu, Chan, Grace, Baye, Estifanos, Workneh, Firehiwot, Asante, Kwaku P., Boanmah-Kaali, Ellen, Adu-Afarwuah, Seth, Dewey, Kathryn G., Gyaase, Stephaney, Wylie, Blair J., Kirkwood, Betty R., Manu, Alexander, Thulasiraj, Ravilla D, Tielsch, James, Chowdhury, Ranadip, Taneja, Sunita, Babu, Giridhara R, Shriyan, Prafulla, Maleta, Kenneth, Mangani, Charles, Acevedo-Gallegos, Sandra, Rodriguez-Sibaja, Maria J., Khatry, Subarna K., LeClerq, Steven C., Mullany, Luke C., Jehan, Fyezah, Ilyas, Muhammad, Rogerson, Stephen J., Unger, Holger W., Ghosh, Rakesh, Musange, Sabine, Ramokolo, Vundli, Zembe-Mkabile, Wanga, Lazzerini, Marzia, Mohamed, Rishard, Wang, Dongqing, Fawzi, Wafaie W., Minja, Daniel T.R., Schmiegelow, Christentze, Masanja, Honorati, Smith, Emily, Lusingu, John P.A., Msemo, Omari A., Kabole, Fathma M., Slim, Salim N., Keentupthai, Paniya, Mongkolchati, Aroonsri, Kajubi, Richard, Kakuru, Abel, Waiswa, Peter, Walker, Dilys, Hamer, Davidson H., Semrau, Katherine E.A., Chaponda, Enesia B., Chico, R. Matthew, Banda, Bowen, Musokotwane, Kebby, Manasyan, Albert, Pry, Jake M., Chasekwa, Bernard, Humphrey, Jean, Shamim, Abu Ahmed, Christian, Parul, Ali, Hasmot, Klemm, Rolf D.W., Massie, Alan B., Mitra, Maithili, Mehra, Sucheta, Schulze, Kerry J., Shamim, Abu Amed, Sommer, Alfred, Ullah, Barkat, West, Keith P., Jr, Begum, Nazma, Chowdhury, Nabidul Haque, Islam, Shafiqul, Mitra, Dipak Kumar, Quaiyum, Abdul, Diseko, Modiegi, Makhema, Joseph, Cheng, Yue, Guo, Yixin, Yuan, Shanshan, Roro, Meselech, Shikur, Bilal, Goddard, Frederick, Haneuse, Sebastien, Hunegnaw, Bezawit, Berhane, Yemane, Worku, Alemayehu, Kaali, Seyram, Arnold, Charles D., Jack, Darby, Amenga-Etego, Seeba, Hurt, Lisa, Shannon, Caitlin, Soremekun, Seyi, Bhandari, Nita, Martines, Jose, Mazumder, Sarmila, Ana, Yamuna, R, Deepa, Hallamaa, Lotta, Pyykkö, Juha, Lumbreras-Marquez, Mario I., Mendoza-Carrera, Claudia E., Hussain, Atiya, Karim, Muhammad, Kausar, Farzana, Mehmood, Usma, Nadeem, Naila, Nisar, Muhammad Imran, Sajid, Muhammad, Mueller, Ivo, Ome-Kaius, Maria, Butrick, Elizabeth, Sayinzoga, Felix, Mariani, Ilaria, Urassa, Willy, Theander, Thor, Deloron, Phillippe, Nielsen, Birgitte Bruun, Muhihi, Alfa, Noor, Ramadhani Abdallah, Bygbjerg, Ib, Moeller, Sofie Lykke, Aftab, Fahad, Ali, Said M., Dhingra, Pratibha, Dhingra, Usha, Dutta, Arup, Sazawal, Sunil, Suleiman, Atifa, Mohammed, Mohammed, Deb, Saikat, Kamya, Moses R., Nakalembe, Miriam, Mulowooz, Jude, Santos, Nicole, Biemba, Godfrey, Herlihy, Julie M., Mbewe, Reuben K., Mweena, Fern, Yeboah-Antwi, Kojo, Bruce, Jane, Chandramohan, Daniel, Prendergast, Andrew, Idueta, Lorena Suárez, Hazel, Elizabeth, Erchick, Daniel J, Yargawa, Judith, Katz, Joanne, Lee, Anne C C, Diaz, Mike, Salasibew, Mihretab, Hayashi, Chika, and Borghi, Elaine
- Published
- 2023
- Full Text
- View/download PDF
12. Biological and pathological mechanisms leading to the birth of a small vulnerable newborn
- Author
-
Ashorn, Per, Black, Robert E, Lawn, Joy E, Ashorn, Ulla, Klein, Nigel, Hofmeyr, G Justus, Temmerman, Marleen, Askari, Sufia, Hunter, Patricia J, Awoyemi, Toluwalase, Ayede, Adejumoke I, Chico, R Matthew, David, Anna L, Dewey, Kathryn G, Duggan, Christopher P, Gravett, Michael, Prendergast, Andrew J, and Ramakrishnan, Usha
- Published
- 2023
- Full Text
- View/download PDF
13. Small vulnerable newborns—big potential for impact
- Author
-
Okwaraji, Yemisrach, Krasevec, Julia, Bradley, Ellen, Conkle, Joel, Stevens, Gretchen, Gatica, Giovanna, Ohuma, Eric O., Coffey, Chris, Estevez Dominguez, Diana, Blencowe, Hannah, Kimathi, Ben, Moller, Ann Beth, Lewin, Alexandra, Hussain-Alkhateeb, Laith, Dalmiya, Nita, Lawn, Joy E., Borghi, Elaine, Hayashi, Chika, Ashorn, Per, Ashorn, Ulla, Muthiani, Yvonne, Aboubaker, Samira, Askari, Sufia, Bahl, Rajiv, Black, Robert E, Duggan, Christopher P, Hofmeyr, G Justus, Kennedy, Stephen H, Klein, Nigel, Lawn, Joy E, Shiffman, Jeremy, Simon, Jonathon, and Temmerman, Marleen
- Published
- 2023
- Full Text
- View/download PDF
14. Evidence-based antenatal interventions to reduce the incidence of small vulnerable newborns and their associated poor outcomes
- Author
-
Ashorn, Per, Black, Robert E, Lawn, Joy E, Ashorn, Ulla, Klein, Nigel, Hofmeyr, G Justus, Temmerman, Marleen, Askari, Sufia, Rogozińska, Ewelina, Heuer, Austin, Walker, Neff, Bhandari, Nita, Bhutta, Zulfiqar A, Koivu, Annariina, Kumar, Somesh, Munjanja, Stephen, Näsänen-Gilmore, Pieta, and Ramogola-Masire, Doreen
- Published
- 2023
- Full Text
- View/download PDF
15. Tranexamic acid at cesarean delivery: drug-error deaths
- Author
-
Moran, Neil F., Bishop, David G., Fawcus, Susan, Morris, Edward, Shakur-Still, Haleema, Devall, Adam J., Gallos, Ioannis D., Widmer, Mariana, Oladapo, Olufemi T., Coomarasamy, Arri, and Hofmeyr, G. Justus
- Published
- 2023
- Full Text
- View/download PDF
16. Tranexamic acid at cesarean delivery: drug-error deaths
- Author
-
Moran, Neil F., Bishop, David G., Fawcus, Susan, Morris, Edward, Shakur-Still, Haleema, Devall, Adam J., Gallos, Ioannis D., Widmer, Mariana, Oladapo, Olufemi T., Coomarasamy, Arri, and Hofmeyr, G. Justus
- Published
- 2022
- Full Text
- View/download PDF
17. Immersion in water during the second stage of labor: a randomized controlled trial
- Author
-
Nikodem, V. Cheryl, Edwards, Sara E., Krzyzanski, Annette M., Berghella, Vincenzo, and Hofmeyr, G. Justus
- Published
- 2022
- Full Text
- View/download PDF
18. Third stage of labor: evidence-based practice for prevention of adverse maternal and neonatal outcomes
- Author
-
Hersh, Alyssa R., Carroli, Guillermo, Hofmeyr, G. Justus, Garg, Bharti, Gülmezoglu, Metin, Lumbiganon, Pisake, De Mucio, Bremen, Saleem, Sarah, Festin, Mario Philip R., Mittal, Suneeta, Rubio-Romero, Jorge Andres, Chipato, Tsungai, Valencia, Catalina, and Tolosa, Jorge E.
- Published
- 2024
- Full Text
- View/download PDF
19. Novel side by side Foley catheter balloons for ‘extended labour induction’: Concept, simulation study and clinical application
- Author
-
Hofmeyr, G. Justus and Dalmacio, Riche
- Published
- 2021
- Full Text
- View/download PDF
20. Incorporating oral PrEP into standard prevention services for South African women: a nested interrupted time-series study
- Author
-
Gichangi, Peter B, Heller, Kate B, Mbandazayo, Nomthandazo, Morrison, Charles S, Nanda, Kavita, Scoville, Caitlin W, Shears, Kathleen, Steyn, Petrus S, Taylor, Douglas, Thomas, Katherine K, Kiarie, James, Justman, Jessica, Nhlabatsi, Zelda, Bekker, Linda-Gail, Nair, Gonasagrie, Hofmeyr, G Justus, Singata-Madliki, Mandisa, Selepe, Raesibe Agnes Pearl, Sibiya, Sydney, Phiri Kasaro, Margaret, Stringer, Jeffrey, Mugo, Nelly R, Donnell, Deborah, Beesham, Ivana, Welch, Julia D, Heffron, Renee, Pleaner, Melanie, Kidoguchi, Lara, Palanee-Phillips, Thesla, Ahmed, Khatija, Baron, Deborah, Bukusi, Elizabeth A, Louw, Cheryl, Mastro, Timothy D, Smit, Jennifer, Batting, Joanne R, Malahleha, Mookho, Bailey, Veronique C, Beksinska, Mags, Rees, Helen, and Baeten, Jared M
- Published
- 2021
- Full Text
- View/download PDF
21. The effect of calcium supplementation on blood pressure in non-pregnant women with previous pre-eclampsia: A randomized placebo-controlled study
- Author
-
Hofmeyr, G Justus, Seuc, Armando, Betrán, Ana Pilar, Cormick, Gabriela, Singata, Mandisa, Fawcus, Sue, Mose, Simpiwe, Frank, Karlyn, Hall, David, Belizán, José, Roberts, James M, Magee, Laura A., and von Dadelszen, Peter
- Published
- 2021
- Full Text
- View/download PDF
22. Sexual behaviour among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Data from the ECHO randomized trial.
- Author
-
Hofmeyr, G. Justus, Singata-Madliki, Mandisa, Batting, Joanne, Steyn, Petrus, Thomas, Katherine K., Issema, Rodal, Beesham, Ivana, Mbatsane, Enough, Morrison, Charles, Deese, Jen, Smit, Jenni, Philip, Neena, Palanee-Phillips, Thesla, Reddy, Krishnaveni, Onono, Maricianah, Mastro, Timothy D., and Baeten, Jared M.
- Subjects
- *
HUMAN sexuality , *CONTRACEPTION , *COPPER intrauterine contraceptives , *INTRAUTERINE contraceptives , *UNSAFE sex , *SEXUAL intercourse , *MEDROXYPROGESTERONE - Abstract
Background: Contraceptive use has complex effects on sexual behaviour and mood, including those related to reduced concerns about unintended pregnancy, direct hormonal effects and effects on endogenous sex hormones. We set out to obtain robust evidence on the relative effects of three contraceptive methods on sex behaviours, which is important for guiding contraceptive choice and future contraceptive developments. Methods: This is a secondary analysis of data from the Evidence for Contraceptive Options and HIV Outcomes (ECHO) randomized trial in which 7,829 HIV-uninfected women from 12 sites in Eswatini, Kenya, South Africa and Zambia seeking contraception were randomly assigned to intramuscular depot-medroxyprogesterone acetate (DMPA-IM), the copper intrauterine device (Cu-IUD) or the levonorgestrel (LNG) implant. Data collected for 12 to 18 months using 3-monthly behavioural questionnaires that relied on recall from the preceding 3 months, were used to estimate relative risk of post-baseline sex behaviours, as well as sexual desire and menstrual bleeding between randomized groups using modified Poisson regression. Results: We observed small but generally consistent effects wherein DMPA-IM users reported lower prevalence of specified high risk sexual behaviours than implant users than Cu-IUD users (the '>' and '<' symbols indicate statistically significant differences): multiple sex partners 3.6% < 4.8% < 6.2% respectively; new sex partner 3.0% < 4.0% <5.3%; coital acts 16.45, 16.65, 17.12 (DMPA-IM < Cu-IUD); unprotected sex 65% < 68%, 70%; unprotected sex past 7 days 33% <36%, 37%; sex during vaginal bleeding 7.1%, 7.1% < 8.9%; no sex acts 4.1%, 3.8%, 3.4% (DMPA-IM > Cu-IUD); partner has sex with others 10% < 11%, 11%. The one exception was having any sex partner 96.5%, 96.9% < 97.4% (DMPA-IM < Cu-IUD). Decrease in sexual desire was reported by 1.6% > 1.1% >0.5%; amenorrhoea by 49% > 41% >12% and regular menstrual pattern by 26% <35% < 87% respectively. Conclusions: These findings suggest that women assigned to DMPA-IM may have a modest decrease in libido and sexual activity relative to the implant, and the implant relative to the Cu-IUD. We found more menstrual disturbance with DMPA-IM than with the implant (and as expected, both more than the Cu-IUD). These findings are important for informing the contraceptive choices of women and policymakers and highlight the need for robust comparison of the effects of other contraceptive methods as well. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. Effects of injectable contraception with depot medroxyprogesterone acetate or norethisterone enanthate on estradiol levels and menstrual, psychological and behavioral measures relevant to HIV risk: The WHICH randomized trial.
- Author
-
Singata-Madliki, Mandisa, Smit, Jenni, Beksinska, Mags, Balakrishna, Yusentha, Avenant, Chanel, Beesham, Ivana, Seocharan, Ishen, Batting, Joanne, Hapgood, Janet P., and Hofmeyr, G. Justus
- Subjects
CONDOM use ,CONTRACEPTION ,ESTRADIOL ,UNSAFE sex ,MEDROXYPROGESTERONE ,HIV ,HUMAN sexuality ,SEXUAL intercourse - Abstract
Background: Observational data suggest lower HIV risk with norethisterone enanthate (NET-EN) than with depo-medroxyprogesterone acetate intramuscular (DMPA-IM) injectable contraceptives. If confirmed, a switch between these similar injectable methods would be programmatically feasible and could impact the trajectory of the HIV epidemic. We aimed in this paper to investigate the effects of DMPA-IM and NET-EN on estradiol levels, measures of depression and sexual activity and menstrual effects, relevant to HIV risk; and to ascertain whether these measures are associated with estradiol levels. Methods: This open-label trial conducted at two sites in South Africa from 5 November 2018 to 30 November 2019, randomized HIV-negative women aged 18–40 to DMPA-IM 150 mg intramuscular 12-weekly (n = 262) or NET-EN 200 mg intramuscular 8-weekly (n = 259). Data were collected on hormonal, behavioral and menstrual effects at baseline and at 25 weeks (25W). Results: At 25W, median 17β estradiol levels were substantially lower than at baseline (p<0.001) for both methods: 76.5 pmol/L (interquartile range (IQR) 54.1 to 104.2) in the DMPA-IM group (n = 222), and 69.8 pmol/L (IQR: 55.1 to 89.3) in the NET-EN group (n = 225), with no statistical difference between the two methods (p = 0.450). Compared with DMPA-IM, NET-EN users reported significantly less amenorrhoea, fewer sexual acts, fewer users reporting at least one act of unprotected sex, more condom use with steady partner, more days with urge for sexual intercourse, more days feeling partner does not love her, and more days feeling sad for no reason. We did not find a clear association between estradiol levels and sexual behavior, depression and menstrual effects. Behavioral outcomes suggest less sexual exposure with NET-EN than DMPA-IM. The strength of this evidence is high due to the randomized study design and the consistency of results across the outcomes measured. Conclusions: Estradiol levels were reduced to postmenopausal levels by both methods. Secondary outcomes suggesting less sexual exposure with NET-EN are consistent with reported observational evidence of less HIV risk with NET-EN. A randomized trial powered for HIV acquisition is feasible and needed to answer this important question. Trial registration: PACTR 202009758229976. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. Effects of depot medroxyprogesterone acetate, the copper IUD and the levonorgestrel implant on testosterone, sex hormone binding globulin and free testosterone levels: ancillary study of the ECHO randomized clinical trial.
- Author
-
Hofmeyr, G. Justus, Singata-Madliki, Mandisa, Batting, Joanne, Balakrishna, Yusentha, and Morroni, Chelsea
- Subjects
- *
INTRAUTERINE contraceptives , *SEX hormones , *ETHINYL estradiol , *COPPER intrauterine contraceptives , *UNSAFE sex , *MEDROXYPROGESTERONE - Abstract
Background: Robust information on relative effects of hormonal contraceptives on endogenous androgens is important for understanding beneficial and adverse effects, method choice and development of new methods. Methods: In this ancillary study at the East London, South Africa site of the ECHO multicentre randomized trial, we compared effects of three contraceptive methods on serum androgen levels among contraceptive users aged 18 to 35 years. Participants were allocated by centrally-managed randomization to open label depot medroxyprogesterone acetate (DMPA-IM), copper intrauterine device (IUD) or levonorgestrel implant. The primary outcome was free testosterone at 6 months. Results: We analysed stored baseline and 6-month serum samples in 398/615 participants (DMPA-IM 131/205, IUD 135/205 and implant 132/205). Median testosterone levels at baseline were DMPA-IM 0.82, IUD 0.9 and implant 0.87 nmol/L; at 6 months, DMPA 0.68 (lower than IUD, mean percentage difference 28.35, (p < 0.001), IUD 0.86 (unchanged) and implant 0.66, lower than IUD, mean percentage difference − 22.98, p < 0.001). Median SHBG levels at baseline were DMPA 52.4, IUD 50.5 and implant 55.75 nmol/L; at 6 months, DMPA 40.65, lower than IUD (mean percentage difference 21.19, p = 0.005), IUD 49.1 (unchanged), and implant 23.35 nmol/L, lower than IUD (mean percentage difference − 50.04, p < 0.001 and than DMPA (mean percentage difference − 39.45, p < 0.001). Free testosterone levels at baseline were DMPA 10, IUD 12 and implant 11 pmol/L; at 6 months, DMPA 11, less than IUD (mean percentage difference 13.53, p = 0.047), IUD 12 and implant 14, higher than IUD (mean percentage difference 14.15, p = 0.038) and than DMPA, (mean percentage difference 29.60, p < 0.001). Conclusions: This is the first randomized trial to show lower SHBG and higher free testosterone with the levonorgestrel implant than with DMPA, and contrasts with reports of increased SHBG with combined oral ethinyl estradiol/levonorgestrel use, and reduced androgens (and impaired sexual function) reported with the etonorgestrel implant. The higher free testosterone with the LNG implant might improve sexual function, mood and bone health as well as increasing side-effects such as acne and hirsutism, and is consistent with the greater sexual activity (with respect to multiple sex partners, new sex partner and unprotected sex) with the implant compared with DMPA documented in the ECHO study. ECHO trial registration: ClinicalTrials.gov, number NCT02550067 15/09/2015. Plain English summary: Contraception, or family planning, is central to the role of women in societies. It is most important to have accurate information on the relative side-effects of various contraceptive options in order to empower women to make informed choices regarding their preferred method. Hormonal contraceptives contain various forms of the female sex hormones, estrogens and/or progestogens. These hormones have direct effects on the users, as well as modifying the levels of the users' own circulating sex hormones, both the 'female' and the 'male' sex hormones (androgens). In this study, consenting participants requesting contraception, were allocated randomly to receive either depot medroxyprogesterone acetate (DMPA-IM) a 3-monthly progestogen injection, the copper intrauterine device (IUD), a non-hormonal contraceptive inserted within the womb, or the levonorgestrel implant, a device placed under the skin which releases a progestogen for 5 years. We measured the participants' androgen levels after 6 months, and found for the first time that the active form of testosterone (free testosterone) was 29% higher with the implant than with DMPA-IM. The level with the IUD was intermediate, and significantly different from the other two methods. This finding is relevant to the effects experienced by users of these methods, because free testosterone has effects on sexual function, bone health and mood, as well as on conditions such as acne and hair distribution patterns. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Behavioral effects of different contraceptive methods and HIV acquisition: an ancillary study of the ECHO randomized trial
- Author
-
Singata-Madliki, Mandisa, Lawrie, Theresa A., Balakrishna, Yusentha, d’Hellencourt, Florence Carayon-Lefebvre, and Hofmeyr, G. Justus
- Published
- 2021
- Full Text
- View/download PDF
26. Misreporting contraceptive use and the association of peak study progestin levels with weight and BMI among women randomized to the progestin-only injectable contraceptives DMPA-IM and NET-EN.
- Author
-
Avenant, Chanel, Bick, Alexis J., Skosana, Salndave B., Dlamini, Sigcinile, Balakrishna, Yusentha, Moliki, Johnson Mosoko, Singata-Madliki, Mandisa, Hofmeyr, G. Justus, Smit, Jenni, Beksinska, Mags, Beesham, Ivana, Seocharan, Ishen, Batting, Joanne, Chen, Pai-Lien, Storbeck, Karl-Heinz, Africander, Donita, and Hapgood, Janet P.
- Subjects
CONTRACEPTION ,CONTRACEPTIVES ,OBESITY in women ,BODY mass index ,WEIGHT loss ,PROGESTATIONAL hormones ,OVERWEIGHT women - Abstract
Progestin-only injectable contraceptives, mainly depo-medroxyprogesterone acetate intramuscular (DMPA-IM), are the most widely used contraceptive methods in sub-Saharan Africa. Insufficient robust data on their relative side-effects and serum concentrations limit understanding of reported outcomes in contraception trials. The WHICH clinical trial randomized HIV-negative women to DMPA-IM (n = 262) or norethisterone enanthate (NET-EN) (n = 259) at two South African sites between 2018–2019. We measured serum concentrations of study and non-study progestins at initiation (D0) and peak serum levels, one week after the 24-week injection [25 weeks (25W)], (n = 435) and investigated associations between study progestin levels, and BMI and weight of participants. Peak median serum concentrations were 6.59 (IQR 4.80; 8.70) nM for medroxyprogesterone (MPA) (n = 161) and 13.6 (IQR 9.01; 19.0) nM for norethisterone (NET) (n = 155). MPA was the most commonly quantifiable non-study progestin at D0 in both arms (54%) and at 25W in the NET-EN arm (27%), followed by NET at D0 in both arms (29%) and at 25W in the DMPA-IM arm (19%). Levonorgestrel was quantifiable in both arms [D0 (6.9%); 25W (3.4%)], while other progestins were quantifiable in ≤ 14 participants. Significant negative time-varying associations were detected between MPA and NET concentrations and weight and BMI in both contraceptive arms and a significant increase was detected for peak serum progestin concentrations for normal weight versus obese women. Contraceptive-related reported outcomes are likely confounded by MPA, more so than NET, with reported DMPA-IM effects likely underestimated, at sites where DMPA-IM is widely used, due to misreporting of contraceptive use before and during trials, and 'tail' effects of DMPA-IM use more than six months before trial enrolment. Peak serum levels of MPA and NET are negatively associated with BMI and weight, suggesting another source of variability between trial outcomes and a potential increase in side-effects for normal weight versus overweight and obese women. Trail registration: The clinical trial was registered with the Pan African Clinical Trials Registry (PACTR 202009758229976). [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
27. Uterotonic Drugs for the Prevention of Postpartum Haemorrhage: A Cost-Effectiveness Analysis
- Author
-
Pickering, Karen, Gallos, Ioannis D., Williams, Helen, Price, Malcolm J., Merriel, Abi, Lissauer, David, Tobias, Aurelio, Hofmeyr, G. Justus, Coomarasamy, Arri, and Roberts, Tracy E.
- Published
- 2019
- Full Text
- View/download PDF
28. Maternal weight and birth outcomes among women on antiretroviral treatment from conception in a birth surveillance study in Botswana
- Author
-
Zash, Rebecca, Caniglia, Ellen C., Diseko, Modiegi, Mayondi, Gloria, Mabuta, Judith, Luckett, Rebecca, Hofmeyr, G Justus, Morroni, Chelsea, Ramogola?Masire, Doreen, Williams, Paige L., Zera, Chloe, Wylie, Blair J., Makhema, Joseph, Lockman, Shahin, and Shapiro, Roger L.
- Subjects
Weight gain -- Health aspects ,Antiviral agents -- Complications and side effects ,Pregnancy, Complications of -- Risk factors ,HIV infection -- Complications and side effects -- Drug therapy ,Health - Abstract
: Introduction: Antiretrovirals such as dolutegravir (DTG) and tenofovir alafenamide (TAF) have been associated with excessive weight gain. The objective of this study was to understand the potential impact of ART‐associated weight gain on pregnancy outcomes among women living with HIV. Methods: Using data from the Tsepamo birth outcomes surveillance study in Botswana, we evaluated the relationship between maternal weight (and weight gain) and severe birth outcomes (very preterm delivery 4000 g) and maternal hypertension. We estimated the relative risk of each outcome by baseline weight (first weight in pregnancy Results: Of 22,828 women on ART at conception with singleton deliveries between August 2014 and April 2020, 16,300 (71.4%) had a weight measured 90 kg) was associated with increased risk of macrosomia (aRR 3.24, 95% CI 2.36, 4.44) and maternal hypertension (aRR 1.79, 95% CI 1.62, 1.97). Baseline weight was not associated with stillbirth or early neonatal death. For all outcomes, second trimester weight gain showed weaker associations than did baseline weight. Duration of pre‐pregnancy ART (years) was associated with higher baseline weight for DTG but not for EFV, and the risk of maternal hypertension by baseline weight category was higher for DTG than EFV for all strata. Conclusions: ART regimens associated with weight gain may reduce the number of women at risk for certain severe adverse pregnancy outcomes associated with low weight but increase the number at risk of macrosomia and maternal hypertension. Further research could determine whether weight‐based ART treatment strategies improve maternal and child health., INTRODUCTION Multiple studies have reported that tenofovir alafenamide (TAF) and dolutegravir (DTG) are associated with clinically significant weight gain, with risk of treatment‐emergent obesity (body mass index, or BMI, >30) [...]
- Published
- 2021
- Full Text
- View/download PDF
29. Pre-eclampsia
- Author
-
Mol, Ben W J, Roberts, Claire T, Thangaratinam, Shakila, Magee, Laura A, de Groot, Christianne J M, and Hofmeyr, G Justus
- Published
- 2016
- Full Text
- View/download PDF
30. Extended pre-exposure prophylaxis with lopinavir–ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial
- Author
-
Van de Perre, Philippe, Nagot, Nicolas, Vallo, Roselyne, Marechal, Valerie, Peries, Marianne, Neveu, Dorine, Foulongne, Vincent, Segondy, Michel, Blanche, Stephane, Treluyer, Jean-Marc, Hirt, Deborah, Tumwine, James K, Ndeezi, Grace, Karamagi, Charles, Musoke, Philippa, Mugaba, Proscovia M, Kwagala, Mary, Murungi, Joan, Muweesi, Hawa Nabuuma, Ninsiima, Evelyn, Baryeija, Simon, Juma, Frederic, Kata, Caleb Bwengye, Katushabe, Stuart, Meda, Nicolas, Ouédraogo, Rasmata, Yé, Diarra, Somé, Eric, Traoré, Hugues A, Nadembega, Christelle, Konaté, Justin, Zongo, Arsène, Ouédraogo, Abass, Néboua, Désiré, Bélemviré, Aissatou, Bambara, Armel, Boncoungou, Justine, Zoungrana, Danielle, Nikodem, Cheryl, Hofmeyr, Justus, Harper, Kim, Jackson, Debra, Sanders, David, Singata, Mandisa, Aku, Amwe, Okegbe-Eze, Collins, Williams, Xoliswa, Mshweshwe, Nolundi, Henge, Vatiswa, Gomba, Fikiswa, Gundu, Tapiwa, Khondowe, Oswell, Kankasa, Chipepo, Mwiya, Mwiya, Lusaka, Mildred, Chizyuka, Mary, Phiri, Mary, Imakando, Billies, Musaku, Mwenechanya, Kapasa, Monica, Rutagwera, David, Clement, Gondwe, Mwaba, Hilton Mwila, Matoba, Japhet, Siuluta, Chafye, Chola, Katai, Mwamutanda, Patricia, Tylleskär, Thorkild, Sommerfelt, Halvor, Engebretsen, Ingunn, Klungsøyr, Jørn, van den Broeck, Jan, Blume, Jörn, Rekacewicz, Claire, Hofmeyr, G Justus, Traore, Hugues, Sunday, Amwe, Some, Eric, Neboua, Desire, Maréchal, Valérie, Engebretsen, Ingunn M S, Lombard, Carl, and Blanche, Stéphane
- Published
- 2016
- Full Text
- View/download PDF
31. Prepregnancy and Early Pregnancy Calcium Supplementation Among Women at High Risk of Pre-eclampsia: A Multicentre, Double-blind, Randomised, Placebo-Controlled Trial
- Author
-
Hofmeyr, G. Justus, Betrán, Ana Pilar, Singata-Madliki, Mandisa, Cormick, Gabriela, Munjanja, Stephen P., Fawcus, Susan, Mose, Simpiwe, Hall, David, Ciganda, Alvaro, Seuc, Armando H., Lawrie, Theresa A., Bergel, Eduardo, Roberts, James M., von Dadelszen, Peter, and Belizán, José M.
- Published
- 2019
- Full Text
- View/download PDF
32. Heat-Stable Carbetocin Versus Oxytocin to Prevent Hemorrhage After Vaginal Birth
- Author
-
Widmer, Mariana, Piaggio, Gilda, Nguyen, Thi M. H., Osoti, Alfred, Owa, Olorunfemi O., Misra, Sujata, Coomarasamy, Arri, Abdel-Aleem, Hany, Mallapur, Ashalata A., Qureshi, Zahida, Lumbiganon, Pisake, Patel, Archana B., Carroli, Guillermo, Fawole, Bukola, Goudar, Shivaprasad S., Pujar, Yeshita V., Neilson, James, Hofmeyr, G. Justus, Su, Lin L., Ferreira de Carvalho, Jose, Pandey, Uma, Mugerwa, Kidza, Shiragur, Shobha S., Byamugisha, Josaphat, Giordano, Daniel, and Gülmezoglu, A. Metin
- Published
- 2018
- Full Text
- View/download PDF
33. The ethical, economic, and developmental imperative to prevent small vulnerable newborns and stillbirths: essential actions to improve the country and global response
- Author
-
Mohiddin, Abdu, Semrau, Katherine E A, Simon, Jonathon, Langlois, Etienne V, Shiffman, Jeremy, Nabwera, Helen, Hofmeyr, G Justus, Lawn, Joy E, Black, Robert E, Askari, Sufia, Klein, Nigel, Ashorn, Ulla, Ashorn, Per, and Temmerman, Marleen
- Published
- 2023
- Full Text
- View/download PDF
34. Integrating oral PrEP delivery among African women in a large HIV endpoint-driven clinical trial
- Author
-
Beesham, Ivana, Welch, Julia D., Heffron, Renee, Pleaner, Melanie, Kidoguchi, Lara, Palanee?Phillips, Thesla, Ahmed, Khatija, Baron, Deborah, Bukusi, Elizabeth A., Louw, Cheryl, Mastro, Timothy D., Smit, Jennifer, Batting, Joanne R., Malahleha, Mookho, Bailey, Veronique C., Beksinska, Mags, Donnell, Deborah, Baeten, Jared M., Kiarie, James, Mugo, Nelly R., Rees, Helen, Justman, Jessica, Nhlabatsi, Zelda, Onono, Maricianah, Bekker, Linda?Gail, Nair, Gonasagrie, Hofmeyr, G Justus, Singata?Madliki, Mandisa, Sibiya, Sydney, Stringer, Jeffrey, Gichangi, Peter B., Heller, Kate B., Mbandazayo, Nomthandazo, Morrison, Charles S., Nanda, Kavita, Scoville, Caitlin W., Shears, Kathleen, Steyn, Petrus S., Taylor, Douglas, Thomas, Katherine K., Selepe, Raesibe Agnes Pearl, and Kasaro, Margaret Phiri
- Subjects
Women -- Health aspects ,Antiviral agents -- Dosage and administration ,Sexually transmitted diseases -- Prevention ,Oral contraceptives -- Usage -- Health aspects ,HIV infection -- Risk factors -- Prevention ,Health - Abstract
: Introduction: Global guidelines emphasize the ethical obligation of investigators to help participants in HIV‐endpoint trials reduce HIV risk by offering an optimal HIV prevention package. Oral pre‐exposure prophylaxis (PrEP) has increasingly become part of state‐of‐the‐art HIV prevention. Here we describe the process of integrating oral PrEP delivery into the HIV prevention package of the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial. Methods: ECHO was an open‐label randomized clinical trial that compared HIV incidence among women randomized to one of three effective contraceptives. In total, 7830 women aged 16 to 35 years from 12 sites in four African countries (Eswatini, Kenya, South Africa and Zambia) were enrolled and followed for 12 to 18 months, from 2015 to 2018. Part‐way through the course of the trial, oral PrEP was provided to study participants either off‐site via referral or on site via trained trial staff. PrEP uptake was compared between different contraceptive users using Chi‐squared tests or t‐tests. HIV seroincidence rates were compared between participants who never versus ever initiated PrEP using exact Poisson regression. Results: PrEP access in ECHO began through public availability in Kenya in May 2017 and was available at all sites by June 2018. When PrEP became available, 3626 (46.3%) eligible women were still in follow‐up in the study, and of these, 622 (17.2%) initiated PrEP. Women initiating PrEP were slightly older; more likely to be unmarried, not living with their partner, having multiple partners; and less likely to be earning their own income and receiving financial support from partners (all p < 0.05). PrEP initiation did not differ across study randomized groups (p = 0.7). Two‐thirds of PrEP users were continuing PrEP at study exit. Conclusions: There is a need for improved HIV prevention services in clinical trials with HIV endpoints, especially trials among African women. PrEP as a component of a comprehensive HIV prevention package provided to women in a large clinical trial is practical and feasible. Provision of PrEP within clinical trials with HIV outcomes should be standard of prevention., Introduction Within the context of clinical trials in which incident HIV infection is a primary study outcome, global guidelines emphasize an ethical imperative to assist participants reduce HIV risk by [...]
- Published
- 2020
- Full Text
- View/download PDF
35. Letter to the editor: Effective and simple interventions to improve outcomes for preterm infants worldwide: The FIGO PremPrep‐5 initiative.
- Author
-
Hofmeyr, G. Justus, Hanson, Sarah Jean, Memo, Ndiwo Baisana, Rubgega, Francois Dudu, and Mercy‐Nkuba, Nassali
- Published
- 2024
- Full Text
- View/download PDF
36. Evidence-based antenatal interventions to reduce the incidence of small vulnerable newborns and their associated poor outcomes.
- Author
-
Hofmeyr, G Justus, Black, Robert E, Rogozińska, Ewelina, Heuer, Austin, Walker, Neff, Ashorn, Per, Ashorn, Ulla, Bhandari, Nita, Bhutta, Zulfiqar A, Koivu, Annariina, Kumar, Somesh, Lawn, Joy E, Munjanja, Stephen, Näsänen-Gilmore, Pieta, Ramogola-Masire, Doreen, and Temmerman, Marleen
- Subjects
- *
UMBILICAL cord clamping , *NEONATAL mortality , *SYPHILIS , *NEWBORN infants , *OMEGA-3 fatty acids , *PRENATAL care , *FAMILY planning services - Abstract
A package of care for all pregnant women within eight scheduled antenatal care contacts is recommended by WHO. Some interventions for reducing and managing the outcomes for small vulnerable newborns (SVNs) exist within the WHO package and need to be more fully implemented, but additional effective measures are needed. We summarise evidence-based antenatal and intrapartum interventions (up to and including clamping the umbilical cord) to prevent vulnerable births or improve outcomes, informed by systematic reviews. We estimate, using the Lives Saved Tool, that eight proven preventive interventions (multiple micronutrient supplementation, balanced protein and energy supplementation, low-dose aspirin, progesterone provided vaginally, education for smoking cessation, malaria prevention, treatment of asymptomatic bacteriuria, and treatment of syphilis), if fully implemented in 81 low-income and middle-income countries, could prevent 5·202 million SVN births (sensitivity bounds 2·398–7·903) and 0·566 million stillbirths (0·208–0·754) per year. These interventions, along with two that can reduce the complications of preterm (<37 weeks' gestation) births (antenatal corticosteroids and delayed cord clamping), could avert 0·476 million neonatal deaths (0·181–0·676) per year. If further research substantiates the preventive effect of three additional interventions (supplementation with omega-3 fatty acids, calcium, and zinc) on SVN births, about 8·369 million SVN births (2·398–13·857) and 0·652 million neonatal deaths (0·181–0·917) could be avoided per year. Scaling up the eight proven interventions and two intrapartum interventions would cost about US$1·1 billion in 2030 and the potential interventions would cost an additional $3·0 billion. Implementation of antenatal care recommendations is urgent and should include all interventions that have proven effects on SVN babies, within the context of access to family planning services and addressing social determinants of health. Attaining high effective coverage with these interventions will be necessary to achieve global targets for the reduction of low birthweight births and neonatal mortality, and long-term benefits on growth and human capital. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
37. Novel Concepts for Intrauterine Device Placement at Caesarean Delivery: Description of Technique and Video Recording.
- Author
-
Hofmeyr, G. Justus and Kime, Kyungu M.
- Subjects
- *
PATIENT aftercare , *OPERATIVE surgery , *INTRAUTERINE contraceptives , *CESAREAN section , *INTERNATIONAL agencies , *CONTRACEPTIVE drugs , *VIDEO recording ,PREVENTION of surgical complications - Abstract
The International Federation of Gynaecology and Obstetrics recommend digital insertion of the copper intrauterine device (IUD) during caesarean delivery and note the risk of thread inclusion in the uterotomy closure and nonvisibility of threads at follow-up. We describe a novel method of inserting the IUD with the insertion straw and directing the lower end of the straw through the cervix for retrieval after the operation, to protect and ensure alignment of the threads. We also describe a simple method of lengthening one thread with part of the other thread, to avoid risks associated with braided suture extensions. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
38. Are women with history of pre-eclampsia starting a new pregnancy in good nutritional status in South Africa and Zimbabwe?
- Author
-
Cormick, Gabriela, Betrán, Ana Pilar, Harbron, Janetta, Dannemann Purnat, Tina, Parker, Catherine, Hall, David, Seuc, Armando H., Roberts, James M., Belizán, José M., Hofmeyr, G. Justus, and on behalf of the Calcium and Pre-eclampsia Study Group
- Published
- 2018
- Full Text
- View/download PDF
39. Improving maternal and perinatal outcomes in the hypertensive disorders of pregnancy: A vision of a community-focused approach
- Author
-
von Dadelszen, Peter, Ansermino, J. Mark, Dumont, Guy, Hofmeyr, G. Justus, Magee, Laura A., Mathai, Matthews, Sawchuck, Diane, Teela, Kate, Donnay, France, and Roberts, James M.
- Published
- 2012
- Full Text
- View/download PDF
40. Evidence for calcium supplementation in pregnancy: More than pre‐eclampsia.
- Author
-
Hofmeyr, G. Justus, Atallah, Alvaro N., and Torloni, M. Regina
- Published
- 2024
- Full Text
- View/download PDF
41. Administration of 400 μg of misoprostol to augment routine active management of the third stage of labor
- Author
-
Hofmeyr, G. Justus, Fawole, Bukola, Mugerwa, Kidza, Godi, N. Patrick, Blignaut, Quentin, Mangesi, Lindeka, Singata, Mandisa, Brady, Leanne, and Blum, Jennifer
- Published
- 2011
- Full Text
- View/download PDF
42. Calcium for pre-eclampsia prevention: A systematic review and network meta-analysis to guide personalised antenatal care.
- Author
-
Woo Kinshella, Mai‐Lei, Sarr, Catherine, Sandhu, Akshdeep, Bone, Jeffrey N., Vidler, Marianne, Moore, Sophie E., Elango, Rajavel, Cormick, Gabriela, Belizan, José M., Hofmeyr, G. Justus, Magee, Laura A., von Dadelszen, Peter, Woo Kinshella, Mai-Lei, and PRECISE Network
- Subjects
PREECLAMPSIA prevention ,META-analysis ,DIETARY supplements ,RESEARCH funding ,DIETARY calcium ,PRENATAL care ,CALCIUM ,PROBABILITY theory - Abstract
Background: Calcium supplementation reduces the risk of pre-eclampsia, but questions remain about the dosage to prescribe and who would benefit most.Objectives: To evaluate the effectiveness of high (≥1 g/day) and low (<1 g/day) calcium dosing for pre-eclampsia prevention, according to baseline dietary calcium, pre-eclampsia risk and co-interventions, and intervention timing.Search Strategy: CENTRAL, PubMed, Global Index Medicus and CINAHL, from inception to 2 February 2021, clinical trial registries, reference lists and expert input (CRD42018111239).Selection Criteria: Randomised controlled trials of calcium supplementation for pre-eclampsia prevention, for women before or during pregnancy. Network meta-analysis (NMA) also included trials of different calcium doses.Data Collection and Analysis: Two independent reviewers extracted published data. The meta-analysis employed random-effects models and the NMA, a Bayesian random-effects model, to obtain direct and indirect effect estimates.Main Results: The meta-analysis included 30 trials (N = 20 445 women), and the NMA to evaluate calcium dosage included 25 trials (N = 15 038). Calcium supplementation prevented pre-eclampsia similarly with a high dose (RR 0.49, 95% CI 0.36-0.66) or a low dose (RR 0.49, 95% CI 0.36-0.65). By NMA, high-dose (vs low-dose) calcium did not differ in effect (RR 0.79, 95% CI 0.43-1.40). Calcium was similarly effective regardless of baseline pre-eclampsia risk, vitamin D co-administration or timing of calcium initiation, but calcium was ineffective among women with adequate average baseline calcium intake.Conclusions: Low- and high-dose calcium supplementation are effective for pre-eclampsia prevention in women with low calcium intake. This has implications for population-level implementation where dietary calcium is low, and targeted implementation where average intake is adequate.Tweetable Abstract: A network meta-analysis of 25 trials found that low-dose calcium supplementation (<1 g/day) is as effective as high-dose calcium supplementation (≥1 g/day) in halving the risk of pre-eclampsia when baseline calcium intake is low. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
43. Misoprostol as an adjunct to standard uterotonics for treatment of post-partum haemorrhage: a multicentre, double-blind randomised trial
- Author
-
Widmer, Mariana, Blum, Jennifer, Hofmeyr, G Justus, Carroli, Guillermo, Abdel-Aleem, Hany, Lumbiganon, Pisake, Ngoc, Nguyen Thi Nhu, Wojdyla, Daniel, Thinkhamrop, Jadsada, Singata, Mandisa, Mignini, Luciano E, Abdel-Aleem, Mahmoud Ahmad, Thach, Tran Son, and Winikoff, Beverly
- Published
- 2010
- Full Text
- View/download PDF
44. Uterine massage to reduce postpartum hemorrhage after vaginal delivery
- Author
-
Abdel-Aleem, Hany, Singata, Mandisa, Abdel-Aleem, Mahmoud, Mshweshwe, Nolundi, Williams, Xoliswa, and Hofmeyr, G. Justus
- Published
- 2010
- Full Text
- View/download PDF
45. Obstetric care in low-resource settings: What, who, and how to overcome challenges to scale up?
- Author
-
Hofmeyr, G. Justus, Haws, Rachel A., Bergström, Staffan, Lee, Anne CC, Okong, Pius, Darmstadt, Gary L., Mullany, Luke C., Oo, Eh Kalu Shwe, and Lawn, Joy E.
- Published
- 2009
- Full Text
- View/download PDF
46. Quality of oxytocin and tranexamic acid for the prevention and treatment of postpartum hemorrhage in Kenya, Nigeria, South Africa, and Tanzania.
- Author
-
Ammerdorffer, Anne, Rushwan, Sara, Timms, Rebecca, Wright, Philip, Beeson, Leanne, Devall, Adam J., Mammoliti, Kristie-Marie, Alwy Al-beity, Fadhlun M., Galadanci, Hadiza, Hofmeyr, G. Justus, Singata-Madliki, Mandisa, Qureshi, Zahida, Lambert, Pete, Gallos, Ioannis D., Coomarasamy, Arri, and Gülmezoglu, A. Metin
- Published
- 2022
- Full Text
- View/download PDF
47. Preventing Perinatal Infections: Need for a Simple, Inexpensive, Safe Intervention That Can Be Used Routinely in All Women
- Author
-
Hofmeyr, G. Justus and McIntyre, James
- Published
- 1997
48. Misoprostol for the prevention and treatment of postpartum haemorrhage
- Author
-
Hofmeyr, G. Justus and Gülmezoglu, A. Metin
- Published
- 2008
- Full Text
- View/download PDF
49. Misoprostol to prevent and treat postpartum haemorrhage: a systematic review and meta-analysis of maternal deaths and dose-related effects/Administration de misoprostol pour prevenir et traiter les hemorragies postpartum, revue systematique et meta-analyse de la mortalite maternelle et des effets dose-dependants/Prevencion y tratamiento de la hemorragia posparto con misoprostol: revision sistematica y metanalisis ..
- Author
-
Hofmeyr, G. Justus, Gulmezoglu, A. Metin, Novikova, Natalia, Linder, Verena, Ferreira, Sandra, and Piaggio, Gilda
- Subjects
Misoprostol -- Dosage and administration ,Misoprostol -- Complications and side effects ,Uterine bleeding -- Prevention ,Uterine bleeding -- Drug therapy ,Mothers -- Patient outcomes ,Mothers -- Prevention - Abstract
Objective To review maternal deaths and the dose-related effects of misoprostol on blood loss and pyrexia in randomized trials of misoprostol use for the prevention or treatment of postpartum haemorrhage. Methods We searched the Cochrane Controlled Trials Register and Pubmed, without language restrictions, for "(misoprostol AND postpartum) OR (misoprostol AND haemorrhage) OR (misoprostol AND hemorrhage)", and we evaluated reports identified through the Cochrane Pregnancy and Childbirth Group search strategy. Randomized trials comparing misoprostol with either placebo or another uterotonic to prevent or treat postpartum haemorrhage were checked for eligibility. Data were extracted, tabulated and analysed with Reviewer Manager (RevMan) 4.3 software. Findings We included 46 trials with more than 40 000 participants in the final analysis. Of 11 deaths reported in 5 trials, 8 occurred in women receiving [greater than or equal to] 600 [micro]g of misoprostol (Peto odds ratio, OR: 2.49; 95% confidence interval, CI: 0.76-8.13). Severe morbidity, defined as the need for major surgery, admission to intensive care, organ failure or body temperature [greater than or equal to] 40 [degrees]C, was relatively infrequent. In prevention trials, severe morbidity was experienced by 16 of 10 281 women on misoprostol and by 16 of 10 292 women on conventional uterotonics; in treatment trials, it was experienced by 1 of 32 women on misoprostol and by 1 of 32 women on conventional uterotonics. Misoprostol recipients experienced more adverse events than placebo recipients: 8 of 2070 versus 5 of 2032, respectively, in prevention trials, and 5 of 196 versus 2 of 202, respectively, in treatment trials. Meta-analysis of direct and adjusted indirect comparisons of the results of randomized trials showed no evidence that 600 [micro]g are more effective than 400 [micro]g for preventing blood loss [greater than or equal to] 1000 ml (relative risk, RR: 1.02; 95% CI: 0.71-1.48). Pyrexia was more than twice as common among women who received [greater than or equal to] 600 [micro]g rather than 400 [micro]g of misoprostol (RR: 2.53; 95% CI: 1.78-3.60). Conclusion Further research is needed to more accurately assess the potential beneficial and harmful effects of misoprostol and to determine the smallest dose that is effective and safe. In this review, 400 [micro]g of misoprostol were found to be safer than [greater than or equal to] 600 [micro]pg and just as effective. Objectif Etudier la mortalite maternelle et les effets dose-dependants du misoprostol sur la perte de sang et la pyrexie dans le cadre d'essais randomises portant sur l'utilisation de ce medicament pour prevenir et traiter les hemorragies postpartum. Methodes Nous avons fait des recherches dans le registre Cochrane des essais controles et dans Pubmed sans emettre de restriction concernant la langue et en utilisant l'expression <> OR (misoprostol AND haemorrhage) OR (misoprostol AND hemorrhage), puis nous avons evalue les rapports identifies avec la strategie de recherche du Groupe Cochrane Pregnancy and Childbirth. Nous avons verifie la conformite avec les criteres d'admissibilite dans l'etude des essais randomises comparant le misoprostol a un placebo ou a un autre uterotonique dans la prevention ou le traitement des hemorragies postpartum. Nous avons extrait et tabule des donnees, puis nous les avons analysees avec le Iogiciel Reviewer Manager (RevMan) 4.3. Resultats Dans l'analyse finale, nous avons pris en compre 46 essais portant sur plus de 40 000 participantes. Sur 11 deces rapportes dans 5 essais, 8 sont survenus chez des femmes ayant recu [greater than or equal to] 600 [micro]g de misoprostol (Odds ratio de Peto, OR : 2,49; intervalle de confiance a 95%, IC: 0,76-8,13). La morbidite grave, definie comme la necessite d'une intervention chirurgicale importante, l'admission en soins intensifs, la defaillance d'un organe ou une temperature corporelle [greater than or equal to] 40 [degrees]C, etait relativement rare. Dans les essais de prevention, nous avons releve une morbidite grave chez 16 des 10281 femmes sous misoprostol et chez 16 des 10292 parturientes recevant un uterotonique classique et, dans les essais therapeutiques, chez une des 32 femmes sous misoprostol et chez une des 32 femmes sous uterotonique classique. Les retomes recevant du misoprostol ont manifeste plus d'effets indesirables que celles recevant un placebo : 8 sur 2070 contre 5 sur 2032 respectivement dans les essais de prevention et 5 sur 196 contre 2 sur 202 dans les essais therapeutiques. La meta-analyse des comparaisons directes et indirectes ajustees des resultats d'essais randomises n'a fait apparaitre aucune preuve d'une efficacite superieure de la dose de 600 [micro]g de misoprostol par rapport a la dose de 400 [micro]g, dans la prevention d'une perte de sang [greater than or equal to]1000 mi (risque relatif, RR : 1,02; IC a 95% : 0,71-1,48). La pyrexie etait plus de deux fois plus frequente chez les femmes ayant recu [greater than or equal to] 600 [micro]g de misoprostol que chez celles ayant recu une dose de 400 pg (RR : 2,53; IC a 95% : 1,78-3,60). Conclusion Des recherches supplementaires sont necessaires pour evaluer plus precisement les effets benefiques et nocifs potentiels du misoprostol et pour identifier la plus faible dose de ce medicament a la fois efficace et sans risque. La presente etude a trouve qu'une dose de 400 [micro]g de misoprostol etait plus sure qu'une dose [greater than or equal to] 600 [micro]g et tout aussi efficace. Objetivo Analizar la mortalidad materna y los efectos dosisdependientes del misoprostol sobre la perdida de sangre y en forma de fiebre en los ensayos aleatorizados realizados sobre su uso con tines de prevencion o tratamiento de la hemorragia posparto. Metodos Utilizamos el Registro de Ensayos Controlados de Cochrane y Pubmed para realizar una busqueda en todos los idiomas planteada en los siguientes terminos: << (misoprostol AND postpartum) OR (misoprostol AND haemorrhage) OR (misoprostol AND hemorrhage) >>. Se procedio a evaluar los trabajos identificados mediante la estrategia de busqueda del Grupo Cochrane de Embarazo y Parto, y se determino la elegibilidad de los ensayos aleatorizados en que se comparo el misoprostol ya fuera con un placebo o con otro uterotonico como forma de prevencion o tratamiento de la hemorragia posparto. Los datos extraidos fueron tabulados y analizados con el software Reviewer Manager (RevMan) 4.3. Resultados Incluimos en el analisis final 46 ensayos que abarcaron a mas de 40 000 participantes. De las 11 defunciones notificadas en 5 ensayos, 8 correspondian a mujeres que habian recibido [greater than or equal to] 600 [micro]g de misoprostol (oportunidad relativa [OR] de Peto: 2,49; intervalo de confianza [IC] del 95%: 0,76-8,13). La morbilidad grave, definida como la necesidad de cirugia mayor, el ingreso en cuidados intensivos, la aparicion de insuficiencia organica o una temperatura corporal [greater than or equal to]40 [degrees]C, fue relativamente poco frecuente. En los ensayos de prevencion, sufrieron morbilidad grave 16 de las 10 281 mujeres a las que se administro misoprostol, y 16 de las 10 292 mujeres sometidas a uterotonicos convencionales; en los ensayos de tratamiento, sufrieron cuadros graves 1 de 32 mujeres sometidas a misoprostol y 1 de 32 mujeres tratadas con uterotonicos convencionales. Quienes recibieron misoprostol sufrieron mas eventos adversos que quienes recibieron placebo: 8 de 2070 frente a 5 de 2032, respectivamente, en los ensayos de prevencion, y 5 de 196 frente a 2 de 202, respectivamente, en los ensayos de tratamiento. El metanalisis de las comparaciones directas e indirectas ajustadas de los resultados de los ensayos aleatorizados no aporto ningun indicio de que la dosis de 600 pg sea mas eficaz que la de 400 [micro]g para prevenir las hemorragias [greater than or equal to]1000 ml (riesgo relativo, RR: 1,02; IC95%: 0,71-1,48). La frecuencia de fiebre entre las mujeres que recibieron [greater than or equal to]600 [micro]g de misoprostol fue mas del doble que en las tratadas con 400 [micro]g (RR: 2,53; IC95%: 1,78-3,60). Conclusion Es necesario realizar nuevas investigaciones para evaluar con mas precision los posibles erectos beneficiosos y nocivos del misoprostol y para determinar la dosis mas baja eficaz y segura. Segun los resultados de este analisis, las dosis de 400 [micro]g de misoprostol son mas seguras que las dosis [greater than or equal to]600 [micro]g y tienen la misma eficacia., Introduction In low-income countries, postpartum haemorrhage is a major cause of maternal death (1) and arguably the most preventable. Attempts to reduce deaths from postpartum haemorrhage have been complicated by [...]
- Published
- 2009
50. Interventions to improve calcium intake through foods in populations with low intake.
- Author
-
Bourassa, Megan W., Abrams, Steven A., Belizán, José M., Boy, Erick, Cormick, Gabriela, Quijano, Carolina Diaz, Gibson, Sarah, Gomes, Filomena, Hofmeyr, G. Justus, Humphrey, Jean, Kraemer, Klaus, Lividini, Keith, Neufeld, Lynnette M., Palacios, Cristina, Shlisky, Julie, Thankachan, Prashanth, Villalpando, Salvador, and Weaver, Connie M.
- Subjects
CALCIUM supplements ,CALCIUM content of food ,ENRICHED foods ,CALCIUM ,BONE health ,FOOD consumption ,FERTILIZERS - Abstract
Calcium intake remains inadequate in many low‐ and middle‐income countries, especially in Africa and South Asia, where average intakes can be below 400 mg/day. Given the vital role of calcium in bone health, metabolism, and cell signaling, countries with low calcium intake may want to consider food‐based approaches to improve calcium consumption and bioavailability within their population. This is especially true for those with low calcium intake who would benefit the most, including pregnant women (by reducing the risk of preeclampsia) and children (by reducing calcium‐deficiency rickets). Specifically, some animal‐source foods that are naturally high in bioavailable calcium and plant foods that can contribute to calcium intake could be promoted either through policies or educational materials. Some food processing techniques can improve the calcium content in food or increase calcium bioavailability. Staple‐food fortification with calcium can also be a cost‐effective method to increase intake with minimal behavior change required. Lastly, biofortification is currently being investigated to improve calcium content, either through genetic screening and breeding of high‐calcium varieties or through the application of calcium‐rich fertilizers. These mechanisms can be used alone or in combination based on the local context to improve calcium intake within a population. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.